摘要
目的对慢性阻塞性肺疾病(COPD)急性发作期采取普米克令舒吸入和静注甲基泼尼松龙治疗的效果进行评析。方法选取我院呼吸内科诊治的COPD患者92例作为研究对象。将其均分成试验组和对比组;两种均进行常规对症治疗,同时试验组采取普米克令舒吸入治疗,对比组采取静注甲基泼尼松龙治疗,在完成治疗后对比分析两组疗效,并掌握两组不良反应发生率。结果治疗后,试验组总有效率达到95.7%,高于对比组的82.6%,差异有统计学意义(P<0.05);试验组不良反应发生率均低于对比组,差异有统计学意义(P<0.05)。结论对COPD急性发作期患者采取雾化吸入普米克令舒治疗效果更确切,可有效改善症状,且安全性更高,优于静注甲基泼尼松龙治疗。
Objective To analyze the effect pulmicort inhalation and intravenous methylprednisolone in the treatment of patients with chronic obstructive pulmonary disease （COPD）-and acute exacerbation. Methods 92 cases of COPD patients treated by respiratory medicine in our hospital were selected as the study subjects. They were divided into test group and contrast group. Two groups were treated with routine symptomatic treatment, while the experimental group adopted pulmicort inhalation treatment, contrast group adopted intravenous methylprednisolone treatment. After the treatment, the efficacy of the two groups was compared and the incidence of adverse reactions in the two groups was mastered. Results After treatment, the total effective rate of the experimental group reached 95.7%, which were higher than 82.6% of the contrast group, the difference was statistically significant （P 〈 0.05）, and the incidence of adverse reactions in the experimental group was lower than that of the contrast group, the difference was statistically significant （P 〈 0.05）. Conclusion COPD patients with acute exacerbation by inhalation of pulmicort treatment is more effective, can effectively improve the symptoms, and higher safety, better than intravenous methylprednisolone treatment.
作者
梁影丽
LIANG Yingli(Department of Infectious Diseases, Changchun Central Hospital, Changchun Jilin 130051, China)
出处
《中国继续医学教育》
2017年第23期177-178,共2页
China Continuing Medical Education
